Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST) Booms on Possible Deal

Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST) stock was up over 155%, to $3.25, before retreating in the first 45 minutes of trading to the $2.25 handle for a 75%+ gain over Friday’s close of $1.27. Volume has been massive – almost 1,900 times the daily average. The move comes after the biopharmaceutical company announced entering into a non-binding, licensing term sheet with a leading China-based pharmaceutical company.

Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST), headquartered in Quebec, Canada, is a biopharmaceutical company that is developing the cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia. This condition affects an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia.

Acasti Deal

At this stage, the licensing deal is non-binding. Upon its execution, the proposed term sheet expects that Acasti would receive an upfront payment of $8 million, additionally there would be regulatory and commercial milestone payments in excess of $125 million, and tiered double-digit royalties on net sales.

The deal grants an exclusive license to the Chinese pharmaceutical company to commercialize CaPre in China and other specified Asian countries. With the high prevalence of hypertriglyceridemia in Asia, this potential partnership presents a significant commercial opportunity for both Acasti Pharma Inc (NASDAQ:ACST) and CaPre.

Acasti’s press release specifies that the deal is not yet agreed to, and conditions and terms may change from those that have been released to the public.

ACST Stock Performance

Shares of Acasti Pharma Inc (NASDAQ:ACST) have been largely flat for the year, losing 5.2% prior to today’s price action. It has been trading in a range between $1.20 and $1.40 for most of 2016 and 2017, but briefly spiked to hit a 52-week high of $2.46.

In August, the company reported its Q1 2018 financial results. Its net loss was C(-$2.8) million or C(-$0.19) per share which was an improvement on its performance for the same period of the prior year when the loss was C(-$3.2) million or C(-$0.29) per share.

Acasti Pharma Inc (NASDAQ:ACST) has a low float figure of 8.1 million shares which makes it a favorite of momentum traders. ACST stock has a Relative Strength Index score of 90 which places it well into the metric’s range that most observers consider to be in “overbought” status.

ACST shares have a listed one-year target share price of $8.21.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.